Skip to main content
Erschienen in: Virchows Archiv 2/2015

01.02.2015 | Original Article

Differential CD133 expression distinguishes malignant from benign papillary lesions of the breast

verfasst von: Chih-Hung Lin, Chia-Hsing Liu, Chien-Hui Wen, Pei-Ling Ko, Chee-Yin Chai

Erschienen in: Virchows Archiv | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Malignant papillary lesions are, in contrast to their benign counterpart, rare malignant tumors in the breast. To differentiate between benign or atypical and malignant papillary lesions can be difficult, especially in core biopsy specimens. In the present study, excisional or more extensive surgical specimens of 33 papillary carcinomas, 2 micropapillary carcinomas, and 17 atypical papillomas of the breast were reviewed and classified according to the latest WHO classification. Thirty-three intraductal papillomas and 49 invasive carcinomas, no special type (NST), were included in the study for comparison. CD133 expression in papillary carcinomas was significantly lower than that in benign and atypical papillomas (p < 0.001). CD133 expression in invasive carcinoma NST was also significantly higher than that in papillary carcinomas. Our data suggests that absence of expression of CD133 can be a useful marker in the differential diagnosis between malignant papillary lesions and their benign or atypical mimics. The characteristic loss of CD133 expression in papillary carcinomas of the breast also indicates that these lesions are distinct from other types of breast cancer.
Literatur
1.
Zurück zum Zitat Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (2012) WHO classification of tumours of the breast, 4th, edth edn. IARC, Lyon Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (2012) WHO classification of tumours of the breast, 4th, edth edn. IARC, Lyon
2.
Zurück zum Zitat Louwman MW, Vriezen M, van Beek MW, Nolthenius-Puylaert MC, van der Sangen MJ, Roumen RM, Kiemeney LA, Coebergh JW (2007) Uncommon breast tumors in perspective: incidence, treatment and survival in the Netherlands. Int J Cancer 121:127–135CrossRefPubMed Louwman MW, Vriezen M, van Beek MW, Nolthenius-Puylaert MC, van der Sangen MJ, Roumen RM, Kiemeney LA, Coebergh JW (2007) Uncommon breast tumors in perspective: incidence, treatment and survival in the Netherlands. Int J Cancer 121:127–135CrossRefPubMed
3.
Zurück zum Zitat McCulloch GL, Evans AJ, Yeoman L, Wilson AR, Pinder SE, Ellis IO, Elston CW (1997) Radiological features of papillary carcinoma of the breast. Clin Radiol 52:865–868CrossRefPubMed McCulloch GL, Evans AJ, Yeoman L, Wilson AR, Pinder SE, Ellis IO, Elston CW (1997) Radiological features of papillary carcinoma of the breast. Clin Radiol 52:865–868CrossRefPubMed
5.
Zurück zum Zitat Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, Guerra R, Sahin AA, Marini FC, Hortobagyi G, Mani SA, Andreeff M (2012) Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest 122:2066–2078CrossRefPubMedCentralPubMed Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, Guerra R, Sahin AA, Marini FC, Hortobagyi G, Mani SA, Andreeff M (2012) Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest 122:2066–2078CrossRefPubMedCentralPubMed
6.
Zurück zum Zitat Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM (2006) Cancer stem cells—perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66:9339–9344CrossRefPubMed Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM (2006) Cancer stem cells—perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66:9339–9344CrossRefPubMed
7.
Zurück zum Zitat Takahashi RU, Takeshita F, Fujiwara T, Ono M, Ochiya T (2011) Cancer stem cells in breast cancer. Cancers (Basel) 3:1311–1328CrossRef Takahashi RU, Takeshita F, Fujiwara T, Ono M, Ochiya T (2011) Cancer stem cells in breast cancer. Cancers (Basel) 3:1311–1328CrossRef
8.
Zurück zum Zitat Iqbal J, Chong PY, Tan PH (2013) Breast cancer stem cells: an update. J Clin Pathol 66:485–490CrossRefPubMed Iqbal J, Chong PY, Tan PH (2013) Breast cancer stem cells: an update. J Clin Pathol 66:485–490CrossRefPubMed
9.
Zurück zum Zitat Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760CrossRefPubMed Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760CrossRefPubMed
10.
Zurück zum Zitat Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1:313–323CrossRefPubMed Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1:313–323CrossRefPubMed
11.
Zurück zum Zitat Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755–768CrossRefPubMed Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755–768CrossRefPubMed
12.
Zurück zum Zitat Zhao P, Lu Y, Jiang X, Li X (2011) Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci 102:1107–1111CrossRefPubMed Zhao P, Lu Y, Jiang X, Li X (2011) Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci 102:1107–1111CrossRefPubMed
13.
Zurück zum Zitat Nadal R, Ortega FG, Salido M, Lorente JA, Rodriguez-Rivera M, Delgado-Rodriguez M, Macia M, Fernandez A, Corominas JM, Garcia-Puche JL, Sanchez-Rovira P, Sole F, Serrano MJ (2013) CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. Int J Cancer 133:2398–2407CrossRefPubMed Nadal R, Ortega FG, Salido M, Lorente JA, Rodriguez-Rivera M, Delgado-Rodriguez M, Macia M, Fernandez A, Corominas JM, Garcia-Puche JL, Sanchez-Rovira P, Sole F, Serrano MJ (2013) CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. Int J Cancer 133:2398–2407CrossRefPubMed
14.
Zurück zum Zitat Pathmanathan N, Albertini AF, Provan PJ, Milliken JS, Salisbury EL, Bilous AM, Byth K, Balleine RL (2010) Diagnostic evaluation of papillary lesions of the breast on core biopsy. Mod Pathol 23:1021–1028CrossRefPubMed Pathmanathan N, Albertini AF, Provan PJ, Milliken JS, Salisbury EL, Bilous AM, Byth K, Balleine RL (2010) Diagnostic evaluation of papillary lesions of the breast on core biopsy. Mod Pathol 23:1021–1028CrossRefPubMed
15.
Zurück zum Zitat Collins LC, Schnitt SJ (2008) Papillary lesions of the breast: selected diagnostic and management issues. Histopathology 52:20–29CrossRefPubMed Collins LC, Schnitt SJ (2008) Papillary lesions of the breast: selected diagnostic and management issues. Histopathology 52:20–29CrossRefPubMed
16.
Zurück zum Zitat Pal SK, Lau SK, Kruper L, Nwoye U, Garberoglio C, Gupta RK, Paz B, Vora L, Guzman E, Artinyan A, Somlo G (2010) Papillary carcinoma of the breast: an overview. Breast Cancer Res Treat 122:637–645CrossRefPubMedCentralPubMed Pal SK, Lau SK, Kruper L, Nwoye U, Garberoglio C, Gupta RK, Paz B, Vora L, Guzman E, Artinyan A, Somlo G (2010) Papillary carcinoma of the breast: an overview. Breast Cancer Res Treat 122:637–645CrossRefPubMedCentralPubMed
17.
Zurück zum Zitat Tokiniwa H, Horiguchi J, Takata D, Kikuchi M, Rokutanda N, Nagaoka R, Sato A, Odawara H, Tozuka K, Oyama T, Takeyoshi I (2011) Papillary lesions of the breast diagnosed using core needle biopsies. Exp Ther Med 2:1069–1072PubMedCentralPubMed Tokiniwa H, Horiguchi J, Takata D, Kikuchi M, Rokutanda N, Nagaoka R, Sato A, Odawara H, Tozuka K, Oyama T, Takeyoshi I (2011) Papillary lesions of the breast diagnosed using core needle biopsies. Exp Ther Med 2:1069–1072PubMedCentralPubMed
18.
Zurück zum Zitat Tse GM, Tan PH, Moriya T (2009) The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast. J Clin Pathol 62:407–413CrossRefPubMed Tse GM, Tan PH, Moriya T (2009) The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast. J Clin Pathol 62:407–413CrossRefPubMed
19.
Zurück zum Zitat Di Cristofano C, Mrad K, Zavaglia K, Bertacca G, Aretini P, Cipollini G, Bevilacqua G, Ben Romdhane K, Cavazzana A (2005) Papillary lesions of the breast: a molecular progression? Breast Cancer Res Treat 90:71–76CrossRefPubMed Di Cristofano C, Mrad K, Zavaglia K, Bertacca G, Aretini P, Cipollini G, Bevilacqua G, Ben Romdhane K, Cavazzana A (2005) Papillary lesions of the breast: a molecular progression? Breast Cancer Res Treat 90:71–76CrossRefPubMed
20.
Zurück zum Zitat Lininger RA, Park WS, Man YG, Pham T, MacGrogan G, Zhuang Z, Tavassoli FA (1998) LOH at 16p13 is a novel chromosomal alteration detected in benign and malignant microdissected papillary neoplasms of the breast. Hum Pathol 29:1113–1118CrossRefPubMed Lininger RA, Park WS, Man YG, Pham T, MacGrogan G, Zhuang Z, Tavassoli FA (1998) LOH at 16p13 is a novel chromosomal alteration detected in benign and malignant microdissected papillary neoplasms of the breast. Hum Pathol 29:1113–1118CrossRefPubMed
21.
Zurück zum Zitat Troxell ML, Levine J, Beadling C, Warrick A, Dunlap J, Presnell A, Patterson J, Shukla A, Olson NR, Heinrich MC, Corless CL (2010) High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. Mod Pathol 23:27–37CrossRefPubMed Troxell ML, Levine J, Beadling C, Warrick A, Dunlap J, Presnell A, Patterson J, Shukla A, Olson NR, Heinrich MC, Corless CL (2010) High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. Mod Pathol 23:27–37CrossRefPubMed
22.
Zurück zum Zitat Aomatsu N, Yashiro M, Kashiwagi S, Takashima T, Ishikawa T, Ohsawa M, Wakasa K, Hirakawa K (2012) CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer. PLoS One 7:e45865CrossRefPubMedCentralPubMed Aomatsu N, Yashiro M, Kashiwagi S, Takashima T, Ishikawa T, Ohsawa M, Wakasa K, Hirakawa K (2012) CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer. PLoS One 7:e45865CrossRefPubMedCentralPubMed
23.
Zurück zum Zitat Ohtsubo I, Ajiki T, Hori Y, Murakami S, Shimizu K, Itoh T, Shimizu M, Fukumoto T, Ku Y (2012) Distinctive expression of CD133 between intraductal papillary neoplasms of the bile duct and bile duct adenocarcinomas. Hepatol Res 42:574–582CrossRefPubMed Ohtsubo I, Ajiki T, Hori Y, Murakami S, Shimizu K, Itoh T, Shimizu M, Fukumoto T, Ku Y (2012) Distinctive expression of CD133 between intraductal papillary neoplasms of the bile duct and bile duct adenocarcinomas. Hepatol Res 42:574–582CrossRefPubMed
24.
Zurück zum Zitat Shimizu K, Itoh T, Shimizu M, Ku Y, Hori Y (2009) CD133 expression pattern distinguishes intraductal papillary mucinous neoplasms from ductal adenocarcinomas of the pancreas. Pancreas 38:e207–e214CrossRefPubMed Shimizu K, Itoh T, Shimizu M, Ku Y, Hori Y (2009) CD133 expression pattern distinguishes intraductal papillary mucinous neoplasms from ductal adenocarcinomas of the pancreas. Pancreas 38:e207–e214CrossRefPubMed
Metadaten
Titel
Differential CD133 expression distinguishes malignant from benign papillary lesions of the breast
verfasst von
Chih-Hung Lin
Chia-Hsing Liu
Chien-Hui Wen
Pei-Ling Ko
Chee-Yin Chai
Publikationsdatum
01.02.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 2/2015
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-014-1695-2

Weitere Artikel der Ausgabe 2/2015

Virchows Archiv 2/2015 Zur Ausgabe

Editorial

In this issue

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …